Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
eugenol + zinc oxide + ferric sulfate
- Development stage
- Unknown
- Lead developer
- Virginia Commonwealth University
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
This combination therapy is used in vital pulp therapy (pulpotomy) for primary molars affected by pulpitis. The procedure involves the application of ferric sulfate, a hemostatic agent that controls bleeding by forming a ferric ion-protein complex that occludes capillary orifices through protein precipitation. Following hemostasis, a base of zinc oxide-eugenol (ZOE), typically in the form of IRM (Intermediate Restorative Material), is applied over the treated pulp tissue. Eugenol provides sedative and antimicrobial effects, though its potential to cause internal resorption has led to clinical comparisons with non-eugenol alternatives. A randomized controlled trial at Virginia Commonwealth University (VCU) specifically compared this ZOE-based regimen against a non-eugenol zinc oxide material (Cavit) to evaluate clinical and radiographic success in children.
- Brand names
- IRM
- Other names
- ZOE with ferric sulfateFerric sulfate pulpotomy with ZOE base
02
Targets
PTGS2 (Prostaglandin-Endoperoxide Synthase 2)COX (Prostaglandin-endoperoxide synthase)TRPA1 (Transient receptor potential cation channel subfamily A member 1)
Beyond the preview
Go deeper on eugenol + zinc oxide + ferric sulfate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on eugenol + zinc oxide + ferric sulfate.